羟基喜树碱、5-氟尿嘧啶、阿霉素联合化疗治疗胃癌的临床观察

HYDROXYL-CAMPTOTHECIN FLUOROURACIL AND ADRIAMYCIN COMBINATION CHEMOTHERAPY IN GASTRIC CANCER:A CLINICAL REPORT OF 42 CASES

目的观察羟基喜树碱（HCPT），5一氟尿嘧啶（5－FU）和阿霉素（ADM）联合化疗治疗胃癌的疗效和耐受性。方法42例胃癌患者接受HCPT10mg静滴，第1～5天；5－FU750mg，静滴第1～3天；ADM50mg静滴第1天的联合化疗。每3周为一疗程。结果可评价疗效患者24例，总缓解率41．7％（10／24），完全缓解率（CR）8．3％（3／24），部分缓解率（PR）33．3％（8／24）。可评价毒性患者42例，白细胞减少发生率为88％（3～4度仅4．7％），血红蛋白减少和血小板减少分别为19％和28．5％。脱发为100％。其他毒副反应少见。结论以HCPT为主组成的FAHCPT方案治疗胃癌有一定疗效，且毒性可耐受。

To assess the antitumor efficacy of and tolerance to the combination of Hydroxyl-camptothecin(HCPT). Fluorouracil (5-FU) and adriamycin (ADM) in gastric cancer. METHODS Between March 1995 andAugust 1996, forty-two patients with gastric cancer received HCPT 10 mg/body/d for 5 consecutive days by intravenous infusion (IV). 5-FU 750 mg/body/d for 3 consecutive days as IV and ADM 50 mg/body on day 1 Ⅳ ev every 3 weeks. RESULTS Twenty-four patients were evaluable for efficacy. The overall response rate was 41. 7%(10/24) and the complete response rate was 8. 3% (2/24). the partial response rate 33. 3% (8/24). 42 patientswere evaluable for toxicity. Leukopenia was observed in 88% of patients, but grade 3 and 4 toxicity in only 4. 7% ofpatients. Anemia and thrombocytopenia were observed in 19% and 21. 4% of patients, respectively. alopecia in100%, which was related to the use of ADM. other side effects were uncommon. CONCLUSION This study showsthat the combination of HCPT, 5-FU and ADM is an active and tolerable regimen for treatment of gastric cancer.